menu

Direct Factor Xa Inhibitors Market

Schedule Call

Direct Factor Xa Inhibitors Market

Direct Factor Xa Inhibitors Market by Indication (Deep Vein Thrombosis, Defibrination Syndrome), Route of Administration (Oral, Parenteral) – Global Outlook & Forecast 2023-2031

GR - 821544 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: May 04, 2023

Historical Years – 2021  |  Base Year – 2022  |  Forecasted Years – 2023-2031


Direct Factor Xa Inhibitors Market Scope

Report Attribute

Details

CAGR

5.8%

Base Year for Estimation

2022

Forecast Period

2023 to 2031

Historical Year

2021

Segments Covered

Indication, Route of Administration, and Region

Regional Scope

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global direct factor Xa inhibitors market is expected to register a revenue CAGR of 5.8% during the forecast period of 2023 to 2031.

Direct Factor Xa Inhibitors Market Fundamentals

Direct factor Xa inhibitors are a class of anticoagulant medications that specifically target and inhibit the activity of factor Xa, an enzyme involved in blood clotting. These medications are used to prevent and treat blood clots, which can lead to serious conditions such as stroke, pulmonary embolism, deep vein thrombosis, and other thromboembolic disorders. Direct factor Xa inhibitors work by directly binding to factor Xa and blocking its activity, thereby preventing the formation of thrombin and the subsequent formation of blood clots. Unlike other anticoagulants such as warfarin and heparin, direct factor Xa inhibitors do not require routine monitoring of blood clotting parameters and have fewer drug interactions.

The research study on the direct factor Xa inhibitors market overview thoroughly analyzes the market and the aspects that either help or hinder the market's growth, such as its drivers, challenges, and opportunities. The research also discusses the list of businesses that operate in this market and their efforts to establish themselves as major players through expansion plans and innovative ideas. It also emphasizes current events that support the market's revenue expansion. The research also analyses how the COVID-19 pandemic has affected society. 

This report is an important tool for the industry stakeholders to gather all the information about the market, customers, and competition. The report also provides the readers with valuable insights on the segmentation, regions, market size & forecast, revenue CAGRs, and other valuable data to help make informed strategic decisions. The study compiles information gathered from industry participants and specialists across the industry value chain. The report also taps into the qualitative and quantitative assessments by industry analysts. Our reports use different methods for estimating the market size and forecast, including secondary research, surveys and interviews, and statistical modeling. With these steps, our reports provide the most accurate market data. These datasets will cumulatively provide in-depth direct factor Xa inhibitors market forecast to the industry stakeholders. 

Direct Factor Xa Inhibitors Market Dynamics 

The rising prevalence of thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, and stroke has eventually resulted in an increased demand for anticoagulant medications, including direct factor Xa inhibitors, and thus are helping in growing the overall growth of global direct factor Xa inhibitors market. For instance, according to the Centre for Disease Control and Prevention article of October 2022, 795,000 individuals suffer from stroke every year in the U.S. Moreover, advances in drug delivery systems and diagnostic technologies have made administering and monitoring direct factor Xa inhibitors easier, further driving the market's growth.

Additionally, drug interactions, high cost, and varying availability in some regions are some restraints impeding the overall direct factor Xa inhibitors market growth. 

Direct Factor Xa Inhibitors Market Ecosystem

Direct Factor Xa Inhibitors Market, by Indication

  • Deep Vein Thrombosis
  • Defibrination Syndrome
  • Myocardial Infarction
  • Others

Direct Factor Xa Inhibitors Market, by Route of Administration

  • Oral
  • Parenteral

Direct Factor Xa Inhibitors Market by Route of Administration

[75675]

The oral route segment dominated the market with the largest revenue share in 2022. The oral direct factor Xa inhibitors currently available in the market include apixaban, edoxaban, and rivaroxaban. The oral route of administration for direct factor Xa inhibitors has several advantages over other formulations, including increased patient convenience and improved treatment adherence. Patients can take oral medications at home without requiring regular visits to a healthcare provider for injections. They have a rapid onset of action, with maximum anticoagulant effects typically achieved within two to four hours of administration. They also have a predictable dose-response relationship, allowing for easier therapeutic effect monitoring.

Segmentation of the market refers to the division of the industry into subgroups based on factors such as indication and route of administration. Market segmentation data helps businesses to understand the preferences and unique needs of different customer groups and develop targeted sales strategies. This information also helps identify potential direct factor Xa inhibitors market growth opportunities. 

Direct Factor Xa Inhibitors Market by Region

North America dominated the global direct factor Xa inhibitors market with the largest revenue share in 2022 due to its high demand for anticoagulant medications and advanced healthcare infrastructure. Another factor driving market expansion is the rising prevalence of venous thromboembolism, a significant cause of morbidity and death in North America. Direct factor Xa inhibitors are considered a safer and more effective alternative to conventional anticoagulants, leading to growing use in the region.

Based on the regions, the global direct factor Xa inhibitors market is segmented into:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • United Kingdom
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific 
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Regional demarcation of the industry will provide information on geographic pockets regarding direct factor Xa inhibitors market outlook, size, share, and growth rate. This data helps businesses evaluate the expansion potential into new regional markets, understand the competitive threats across different regions, and develop localized sales and expansion strategies. 

Key Components of the Report 

  • In-depth review of the prevalent market trends
  • Annualized market size and forecast of every segment across 5 regions and 14 countries from 2021 to 2031.
  • Market-specific analysis of the segments on a global level and further elaboration of trends in each region and country
  • Competitive landscape of key players in the global market, based on market share or competitive positioning.
  • Profiles of major market players based on the business landscape, financial growth, and depth of product portfolio.

Direct Factor Xa Inhibitors Market Competitive Landscape 

Janssen Pharmaceuticals (Johnson & Johnson Services Inc.), Mylan N.V., Bayer AG, GSK plc,Daiichi Sankyo Company Limited, Dr.Reddy's Laboratories Ltd., Pfizer Limited., Bristol-Myers Squibb Company, Boehringer Ingelheim, Amphastar Pharmaceuticals, Inc., Leo Pharma Inc. and others.

The market competitive landscape is performed by collecting and analyzing information about the key competitors, the present industry trends, and market dynamics. It includes information collection and analysis on products, pricing, geographic outreach, customer demographics, marketing strategies, and recent developments. Competitive landscape assessment will help businesses identify the current prevalent or potential opportunities and threats, considering the direct factor Xa inhibitors industry trends. 

Direct Factor Xa Inhibitors Market Strategic Developments

  • In December 2021, Janssen Pharmaceutical Companies of Johnson & Johnson received FDA approval for two new pediatric XARELTO (rivaroxaban) indications. The first indication was for treating blood clots and preventing recurrent blood clots in patients from birth to under 18 years of age, following initial parenteral anticoagulant treatment for at least five days. The second indication was preventing blood clots and related events in children aged two years and older with congenital heart disease who underwent the Fontan procedure. XARELTO is the only direct oral anticoagulant with FDA approval for the primary prevention of clots in pediatric patients following the Fontan procedure. Furthermore, XARELTO is the only DOAC in the US market that offers an oral suspension formulation for flexible dosing based on body weight, making it an attractive treatment option for pediatric patients.

Key Strengths of Our Report 

  • Forecast till 2031
  • Cross-sectional Coverage Across 14 Countries
  • Consumer Level Segmentation
  • Regulatory Landscape
  • Key Cross Competition
  • Unmet Needs
  • Market Attractiveness
  • Analysis of Pipeline Prospects
  • Market Drivers and Challenges

Target Audience to Benefit from this Report.

  • New entrants to the market, start-ups, investors, and equity firms
  • Manufacturers, distributors, developers, and regulators of products. Research and consulting firms
  • Associations and governmental bodies 
  • Business associations, forums, lobbying groups, and reporting organizations

Reasons to Buy this Report

  • Detailed analysis of the impact of the COVID-19 pandemic on the global direct factor Xa inhibitors market
  • Develop your growth strategies by reviewing the prevalent market trends, innovations, segment analysis, regional market landscape, and future opportunities.
  • Information on relevant laws and regulations that impact the market, such as product safety standards or import/export regulations.
  • Understanding the market's future competitive landscape and providing an insightful analysis of the major industry drivers and obstacles.
  • Identify the competitive landscape of the global market and understand the intensity of competition. 
  • Finding established and promising new competitors in the market will aid in creating competitive advantage tactics.
  • Track the revenue growth of the global, regional, and country-level markets and make effective expansion decisions.
  • Strategize sales and marketing goals by determining the most premium opportunities in the direct factor Xa inhibitors market.
  • Evaluate potential return on investment for new products or services by analyzing CAGR data, businesses can evaluate the potential return on investment.
  • Our robust sources and research methodologies deliver accurate market sizing and forecast, which are further validated by authentic primary sources, including CMOs from major market players and key opinion leaders.

Frequently Asked Questions About This Report

Direct factor Xa inhibitors are a class of anticoagulant medications that specifically target and inhibit the activity of factor Xa, an enzyme involved in the blood clotting.

North American region will have the largest direct factor Xa inhibitors market size during the forecast period from 2023 to 2031.

The revenue CAGR of the direct factor Xa inhibitors market during the forecast period will be 5.8% from 2023 to 2031.

The increasing interest in personalized medicine is the most direct factor Xa inhibitors industry trend.

The increasing incidence of thromboembolic disorders and an aging population are some growth opportunities in the global direct factor Xa inhibitors market.

The drug interactions, high cost, and varying availability in developing nations are key challenges hampering the growth of the global direct factor Xa inhibitors market.

Technological advancements and increased awareness drive the global direct factor Xa inhibitors market.

Some prominent players in the direct factor Xa inhibitors market are Pfizer Limited., Bristol-Myers Squibb Company, Boehringer Ingelheim, Amphastar Pharmaceuticals, Inc., and Leo Pharma Inc.

The route of administration segment has the highest share in the global direct factor Xa inhibitors market.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    3. Regulatory Landscape
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL DIRECT FACTOR XA INHIBITORS MARKET- ANALYSIS & FORECAST, BY INDICATION
    1. Deep Vein Thrombosis
    2. Defibrination Syndrome
    3. Myocardial Infarction 
    4. Others
  6. GLOBAL DIRECT FACTOR XA INHIBITORS MARKET- ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION
    1. Oral
    2. Parenteral     
  7. GLOBAL DIRECT FACTOR XA INHIBITORS MARKET - ANALYSIS & FORECAST, BY REGION
    1. North America Direct Factor Xa Inhibitors Market
      1. North America Direct Factor Xa Inhibitors Market, by Indication 
      2. North America Direct Factor Xa Inhibitors Market, by Route of Administration
      3. North America Direct Factor Xa Inhibitors Market, by Country
        1. U.S.
          1. U.S. Direct Factor Xa Inhibitors Market, by Indication 
          2. U.S. Direct Factor Xa Inhibitors Market, by Route of Administration
        2. Canada
          1. Canada Direct Factor Xa Inhibitors Market, by Indication 
          2. Canada Direct Factor Xa Inhibitors Market, by Route of Administration
    2. Europe Direct Factor Xa Inhibitors Market
      1. Europe Direct Factor Xa Inhibitors Market, by Indication 
      2. Europe Direct Factor Xa Inhibitors Market, by Route of Administration 
      3. Europe Direct Factor Xa Inhibitors Market, by Country/Region
        1. Germany
          1. Germany Direct Factor Xa Inhibitors Market, by Indication 
          2. Germany Direct Factor Xa Inhibitors Market, by Route of Administration
        2. U.K.
          1. U.K. Direct Factor Xa Inhibitors Market, by Indication 
          2. U.K. Direct Factor Xa Inhibitors Market, by Route of Administration
        3. France
          1. France Direct Factor Xa Inhibitors Market, by Indication 
          2. France Direct Factor Xa Inhibitors Market, by Route of Administration
        4. Spain
          1. Spain Direct Factor Xa Inhibitors Market, by Indication 
          2. Spain Direct Factor Xa Inhibitors Market, by Route of Administration
        5. Italy
          1. Italy Direct Factor Xa Inhibitors Market, by Indication 
          2. Italy Direct Factor Xa Inhibitors Market, by Route of Administration
        6. Rest of Europe 
          1. Rest of Europe Direct Factor Xa Inhibitors Market, by Indication 
          2. Rest of Europe Direct Factor Xa Inhibitors Market, by Route of Administration
    3. Asia Pacific Direct Factor Xa Inhibitors Market
      1. Asia Pacific Direct Factor Xa Inhibitors Market, by Indication 
      2. Asia Pacific Direct Factor Xa Inhibitors Market, by Route of Administration
      3. Asia Pacific Direct Factor Xa Inhibitors Market, by Country/Region
        1. China
          1. China Direct Factor Xa Inhibitors Market, by Indication 
          2. China Direct Factor Xa Inhibitors Market, by Route of Administration
        2. Japan
          1. Japan Direct Factor Xa Inhibitors Market, by Indication 
          2. Japan Direct Factor Xa Inhibitors Market, by Route of Administration 
        3. India
          1. India Direct Factor Xa Inhibitors Market, by Indication 
          2. India Direct Factor Xa Inhibitors Market, by Route of Administration
        4. South Korea
          1. South Korea Direct Factor Xa Inhibitors Market, by Indication 
          2. South Korea Direct Factor Xa Inhibitors Market, by Route of Administration
        5. Australia
          1. Australia Direct Factor Xa Inhibitors Market, by Indication 
          2. Australia Direct Factor Xa Inhibitors Market, by Route of Administration
        6. Rest of Asia Pacific
          1. Rest of Asia Pacific Direct Factor Xa Inhibitors Market, by Indication 
          2. Rest of Asia Pacific Direct Factor Xa Inhibitors Market, by Route of Administration
    4. Latin America Direct Factor Xa Inhibitors Market
      1. Latin America Direct Factor Xa Inhibitors Market, by Indication 
      2. Latin America Direct Factor Xa Inhibitors Market, by Route of Administration
      3. Latin America Direct Factor Xa Inhibitors Market, by Country/ Region
        1. Brazil
          1. Brazil Direct Factor Xa Inhibitors Market, by Indication 
          2. Brazil Direct Factor Xa Inhibitors Market, by Route of Administration
        2. Mexico
          1. Mexico Direct Factor Xa Inhibitors Market, by Indication 
          2. Mexico Direct Factor Xa Inhibitors Market, by Route of Administration 
        3. Argentina
          1. Argentina Direct Factor Xa Inhibitors Market, by Indication 
          2. Argentina Direct Factor Xa Inhibitors Market, by Route of Administration
        4. Rest of Latin America
          1. Rest of Latin America Direct Factor Xa Inhibitors Market, by Indication 
          2. Rest of Latin America Direct Factor Xa Inhibitors Market, by Route of Administration 
    5. Middle East & Africa Direct Factor Xa Inhibitors Market
      1. Middle East & Africa Direct Factor Xa Inhibitors Market, by Indication 
      2. Middle East & Africa Direct Factor Xa Inhibitors Market, by Route of Administration
      3. Middle East & Africa Direct Factor Xa Inhibitors Market, by Country/ Region
        1. GCC Countries
          1. GCC Countries Direct Factor Xa Inhibitors Market, by Indication 
          2. GCC Countries Direct Factor Xa Inhibitors Market, by Route of Administration
        2. South Africa
          1. South Africa Direct Factor Xa Inhibitors Market, by Indication 
          2. South Africa Direct Factor Xa Inhibitors Market, by Route of Administration 
        3. Rest of Middle East & Africa
          1. Rest of Middle East & Africa Direct Factor Xa Inhibitors Market, by Indication 
          2. Rest of Middle East & Africa Direct Factor Xa Inhibitors Market, by Route of Administration
  8. COMPANY PROFILES         
    1. Janssen Pharmaceuticals (Johnson & Johnson Services Inc.)
      1. Business Snapshot 
      2. Products Offered
      3. Financial Details
      4. Strategic Development
    2. GSK Plc
    3. Dr.Reddy's Laboratories Ltd.
    4. Mylan N.V.
    5. Bayer AG
    6. Daiichi Sankyo Company Limited
    7. Pfizer Limited.
    8. Bristol-Myers Squibb Company
    9. Boehringer Ingelheim
    10. Amphastar Pharmaceuticals, Inc.
    11. Leo Pharma Inc.

*Insights on financial performance are subject to the availability of information in the public domain

List of Tables

 

  1. Global Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million)
  2. Global Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  3. Global Direct Factor Xa Inhibitors Market, by Region, 2021-2031 (US$ Million) 
  4. North America Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  5. North America Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  6. North America Direct Factor Xa Inhibitors Market, by Country, 2021-2031 (US$ Million)
  7. U.S. Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  8. U.S. Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  9. Canada Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  10. Canada Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  11. Europe Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  12. Europe Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  13. Europe Direct Factor Xa Inhibitors Market, by Country/ Region, 2021-2031 (US$ Million) 
  14. Germany Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  15. Germany Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  16. U.K. Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  17. U.K. Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  18. France Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  19. France Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  20. Italy Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  21. Italy Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  22. Spain Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  23. Spain Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  24. Rest of Europe Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  25. Rest of Europe Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  26. Asia Pacific Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  27. Asia Pacific Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  28. Asia Pacific Direct Factor Xa Inhibitors Market, by Country/ Region, 2021-2031 (US$ Million) 
  29. China Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  30. China Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  31. Japan Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  32. Japan Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  33. India Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  34. India Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  35. South Korea Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  36. South Korea Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  37. Australia Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  38. Australia Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  39. Rest of Asia Pacific Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  40. Rest of Asia Pacific Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  41. Latin America Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  42. Latin America Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  43. Latin America Direct Factor Xa Inhibitors Market, by Country/ Region, 2021–2031 (US$ Million)
  44. Brazil Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  45. Brazil Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  46. Mexico Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  47. Mexico Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  48. Argentina Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  49. Argentina Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  50. Rest of Latin America Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  51. Rest of Latin America Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  52. Middle East and Africa Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  53. Middle East and Africa Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  54. Middle East and Africa Direct Factor Xa Inhibitors Market, by Country/ Region, 2021–2031 (US$ Million)
  55. GCC Countries Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  56. GCC Countries Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  57. South Africa Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  58. South Africa Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 
  59. Rest of Middle East & Africa Direct Factor Xa Inhibitors Market, by Indication, 2021-2031 (US$ Million) 
  60. Rest of Middle East & Africa Direct Factor Xa Inhibitors Market, by Route of Administration, 2021–2031 (US$ Million) 

List of Figures

 

  1. Direct Factor Xa Inhibitors Market Ecosystem  
  2. Snapshot of Global Direct Factor Xa Inhibitors Market, 2021 & 2031 
  3. Snapshot of Global Direct Factor Xa Inhibitors Market, by Region, 2021 & 2031 
  4. Global Direct Factor Xa Inhibitors Market: COVID-19 Pandemic Impact Assessment 
  5. Global Direct Factor Xa Inhibitors Market: Key Players & Competitive Positioning (2022) 
  6. Direct Factor Xa Inhibitors: Market Dynamics 
  7. Global Direct Factor Xa Inhibitors Treatment Market for Deep Vein Thrombosis, 2021-2031 (US$ Million)
  8. Global Direct Factor Xa Inhibitors Treatment Market for Defibrination Syndrome, 2021-2031 (US$ Million)
  9. Global Direct Factor Xa Inhibitors Treatment Market for Myocardial Infarction, 2021-2031 (US$ Million)
  10. Global Direct Factor Xa Inhibitors Treatment Market for Others, 2021-2031 (US$ Million)
  11. Global Direct Factor Xa Inhibitors Treatment Market for Oral, 2021-2031 (US$ Million)
  12. Global Direct Factor Xa Inhibitors Treatment Market for Parenteral, 2021-2031 (US$ Million)
  13. North America Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  14. U.S. Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  15. Canada Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  16. Europe Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  17. Germany Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  18. U.K. Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  19. France Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  20. Italy Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  21. Spain Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  22. Rest of Europe Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  23. Asia Pacific Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  24. China Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  25. Japan Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  26. India Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  27. South Korea Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  28. Australia Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  29. Rest of Asia Pacific Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  30. Latin America Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  31. Brazil Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  32. Mexico Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  33. Argentina Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million)
  34. Rest of Latin America Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million)
  35. Middle East & Africa Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  36. GCC Countries Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  37. South Africa Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million) 
  38. Rest of Middle East & Africa Direct Factor Xa Inhibitors Market, 2021-2031 (US$ Million)
  39. Janssen Pharmaceuticals (Johnson & Johnson Services Inc.) Revenue from 2019 Onwards (US$ Million)
  40. GSK Plc Revenue from 2019 Onwards (US$ Million)
  41. Dr.Reddy's Laboratories Ltd. Revenue from 2019 Onwards (US$ Million)
  42. Mylan N.V. Revenue from 2019 Onwards (US$ Million)
  43. Bayer AG Revenue from 2019 Onwards (US$ Million)
  44. Daiichi Sankyo Company Limited Revenue from 2019 Onwards (US$ Million)
  45. Pfizer Limited Revenue from 2019 Onwards (US$ Million)
  46. Bristol-Myers Squibb Company Revenue from 2019 Onwards (US$ Million)
  47. Boehringer Ingelheim Revenue from 2019 Onwards (US$ Million)
  48. Amphastar Pharmaceuticals, Inc. Revenue from 2019 Onwards (US$ Million)
  49. Leo Pharma Inc. Revenue from 2019 Onwards (US$ Million)

Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the Direct Factor Xa Inhibitors Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the Direct Factor Xa Inhibitors Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?

Recommended Reports